


CLAIMS

1.- Sulfonamide compounds of general formula (Ia),



(Ia)

5 wherein

10 R^1 represents a $-NR^7R^8$ radical or a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as a ring member containing cycloaliphatic radical, which may be condensed with a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as a ring member containing mono- or bicyclic cycloaliphatic ring system,

15 R^2 , R^3 , R^4 , R^5 and R^6 , identical or different, each represent hydrogen, halogen, cyano, nitro, a saturated or unsaturated, linear or branched aliphatic radical, a linear or branched alkoxy radical, a linear or branched alkylthio radical, hydroxy, trifluoromethyl, a saturated or unsaturated cycloaliphatic radical, an alkylcarbonyl radical, a phenylcarbonyl or a $-NR^9R^{10}$ group,

20 R^7 and R^8 , identical or different, each represent hydrogen or a saturated or unsaturated, optionally at least mono-substituted linear or branched aliphatic radical,

25

with the proviso that R^8 and R^9 are not hydrogen at the same time, and if one of them, R^8 or R^9 , is a saturated or unsaturated, linear or branched, optionally at least mono-substituted C_1 - C_4 aliphatic radical, the other one is a saturated or unsaturated, linear or branched, optionally at least
5 mono-substituted aliphatic radical with at least five carbon atoms,

or

R^7 and R^8 , together with the bridging nitrogen atom form a saturated or
10 unsaturated, optionally at least mono-substituted, optionally at least one further heteroatom as a ring member containing heterocyclic ring which may be condensed with a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as a ring member containing mono- or bicyclic cycloaliphatic ring system,

15 R^9 and R^{10} , identical or different, each represent hydrogen or a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical,

20 or

R^9 and R^{10} , together with the bridging nitrogen atom form a saturated or
25 unsaturated, optionally at least mono-substituted, optionally at least one further heteroatom as a ring member containing heterocyclic ring which may be condensed with a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as a ring member containing mono- or bicyclic cycloaliphatic ring system,

30 A and B, identical or different, each represent a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical

or

A and B, together with the carbon atom to which they are bonded, form a saturated or unsaturated, but not aromatic, optionally at least mono-substituted cycloalkyl ring,

5

and

n is 0,

10

optionally in form of one of their stereoisomers, preferably enantiomers or diastereomers, their racemate or in form of a mixture of at least two of their stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or a salt thereof, preferably a corresponding physiologically acceptable salt thereof or a corresponding solvate thereof.

15


2. The compounds according to claim 1, characterized in that R^1 represents a $-NR^7R^8$ radical or a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as a ring member containing 5- or 6-membered cycloaliphatic radical, which may be condensed with a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as a ring member containing mono- or bicyclic cycloaliphatic ring system, whereby the rings of the ring system are 5- or 6-membered,

20

25

preferably a NR^7R^8 radical or a radical chosen from the group consisting of

-52-



wherein, if present, the dotted line represents an optional chemical bond, and R^{19} represents hydrogen, a linear or branched C_1 - C_6 alkyl radical or a benzyl radical, preferably hydrogen or a C_1 - C_2 alkyl radical.

5

- 3.- The compounds according to claim 1 or 2, characterized in that R^2 , R^3 , R^4 , R^5 and R^6 , identical or different, each represent hydrogen, F, Cl, Br, cyano, nitro, a linear or branched C_{1-6} alkyl radical, a linear or branched C_{2-6} alkenyl radical, a linear or branched C_{2-6} alkynyl radical, a linear or branched C_{1-6} alkoxy, a linear or branched C_{1-6} alkylthio, hydroxy, trifluoromethyl, a saturated or unsaturated C_{3-8} cycloaliphatic radical, a linear or branched C_{1-6} alkylcarbonyl radical, phenylcarbonyl or an $-NR^9R^{10}$ group,

10

15 preferably H, F, Cl, NO_2 , NH_2 or a C_{1-2} alkyl radical.

- 4.- The compounds according to one or more of claims 1 to 3, characterized in that R^7 and R^8 , identical or different, each represent hydrogen, a linear or branched, optionally at least mono-substituted C_{1-10} alkyl radical, a linear or branched, optionally at least mono-substituted, C_{2-10} alkenyl radical, or a linear or branched, optionally at least mono-substituted, C_{2-10} alkynyl radical or


20

25

R^7 and R^8 , together with the bridging nitrogen form a saturated or unsaturated, optionally at least mono-substituted, optionally at least one further heteroatom as a ring member containing 5- or 6-membered heterocyclic ring which may be condensed with a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as a ring member containing mono- or bicyclic cycloaliphatic ring system, whereby the rings of the ring system are 5- 6- or 7-membered.

- 10 5.- The compounds according to claim 4, characterized in that R^7 and R^8 , identical or different, each represent hydrogen or a linear or branched C_1 -
10 alkyl radical or

15 R^7 and R^8 , together with the bridging nitrogen atom form a radical chosen from the group consisting of




wherein R^{20} , if present, is hydrogen, a linear or branched C_1 - C_6 alkyl radical or a benzyl radical, preferably hydrogen, or a C_1 - C_2 alkyl radical.

- 6.- The compounds according to one or more of claims 1 to 5, characterized in that R^9 and R^{10} , identical or different, each represent hydrogen, a linear or branched, optionally at least mono-substituted C_1 - C_{10} alkyl radical, a linear or branched, optionally at least mono-substituted C_2 - C_{10} alkenyl radical or a linear or branched, optionally at least mono-substituted C_2 - C_{10} alkynyl radical or

R^9 and R^{10} , together with the bridging nitrogen atom form a saturated or unsaturated, optionally at least mono-substituted, optionally at least one further heteroatom as a ring member containing 5- or 6-membered heterocyclic ring, which may be condensed with a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as a ring member containing mono- or bicyclic cycloaliphatic ring system whereby the rings of the ring system are 5- 6- or 7-membered.

- 7.- The compounds according to claim 6, characterized in that R^9 and R^{10} , identical or different, each represent hydrogen or a linear or branched C_1 - C_{10} alkyl radical, or

R^9 and R^{10} , together with the bridging nitrogen atom form a radical chosen from a group consisting of




wherein R^{20} , if present, is hydrogen, a linear or branched C_1 - C_6 alkyl radical or a benzyl radical, preferably hydrogen, or a C_1 - C_2 alkyl radical.

- 8.- The compounds according to one or more of claims 1-7, characterized in that A and B, identical or different, each represent a linear or branched C₁-C₆ alkyl radical, a linear or branched C₂-C₆ alkenyl radical or a linear or branched C₂-C₆ alkynyl radical,
5 preferably a linear or branched C₁-C₆ alkyl radical, or
- A and B, together with the carbon atom to which they are bonded, form a saturated or unsaturated, but not aromatic, optionally at least mono-substituted cycloalkyl ring,
10 preferably a C₃-C₈ cycloalkyl ring,
more preferably a cyclohexyl ring.
15
- 9.- The compounds according to one or more of claims 1-8, characterized in that the compound is selected from a group consisting of
- 20 [1] 1-Cyclohexanesulfonyl-3-(1-methyl-1,2,3,6-tetrahydropyridine-4-yl)-5-nitro-1H-indole,
[2] 5-Chloro-1-cyclohexanesulfonyl-3-(1-methyl-1,2,3,6-tetrahydropyridine-4-yl)-1H-indole,
25 [3] 5-Amino-1-cyclohexanesulfonyl-3-(1-methyl-1,2,3,6-tetrahydropyridine-4-yl)-1H-indole and
[4] 1-Cyclohexanesulfonyl-5-fluoro-3-(1,2,3,5,8,8a-hexahydro-indolizine-7-yl)-1H-indole hydrochloride
30 and their corresponding salts and solvates.

-56-

10.- Sulfonamide compounds of general formula (Ib),



(Ib)

wherein

5

R^1 is a $-NR^7R^8$ radical,

10

R^2 , R^3 , R^4 , R^5 and R^6 , identical or different, each represent hydrogen, halogen, cyano, nitro, a saturated or unsaturated, linear or branched aliphatic radical, a linear or branched alkoxy radical, a linear or branched alkylthio radical, hydroxy, trifluoromethyl, a saturated or unsaturated cycloaliphatic radical, an alkylcarbonyl radical, a phenylcarbonyl or a $-NR^9R^{10}$ group,

15

R^7 and R^8 , identical or different, each represent hydrogen or a saturated or unsaturated, optionally at least mono-substituted linear or branched C_{1-4} aliphatic radical,

20

R^9 and R^{10} , identical or different, each represent hydrogen or a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical,

or

25

R⁹ and R¹⁰, together with the bridging nitrogen atom form a saturated or unsaturated, optionally at least mono-substituted, optionally at least one further heteroatom as a ring member containing heterocyclic ring which may be condensed with a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as a ring member containing mono- or bicyclic cycloaliphatic ring system,

A and B, identical or different, each represent a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical

or

A and B, together with the carbon atom to which they are bonded, form a saturated or unsaturated, but not aromatic, optionally at least mono-substituted cycloalkyl ring,

and

n is 0;

optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, their racemate or in form of a mixture of at least two of their stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or a salt thereof, preferably a corresponding physiologically acceptable salt thereof or a corresponding solvate thereof.

11.- The compounds according to claim 10, characterized in that R^2 , R^3 , R^4 , R^5 and R^6 , identical or different, each represent hydrogen, F, Cl, Br, cyano, nitro, a linear or branched C_1 - C_6 alkyl radical, a linear or branched C_2 - C_6 alkenyl radical, a linear or branched C_2 - C_6 alkynyl radical, a linear or branched C_1 - C_6 -alkoxy, a linear or branched C_1 - C_6 -alkylthio, hydroxy, trifluoromethyl, a saturated or unsaturated C_3 - C_8 cycloaliphatic radical, a linear or branched C_1 - C_6 -alkylcarbonyl radical, phenylcarbonyl or an $-NR^9R^{10}$ group,

preferably H, F, Cl, NO_2 , NH_2 or a C_1 - C_2 alkyl radical.

12.- The compounds according to claim 10 or 11, characterized in that R^7 and R^8 , identical or different, wherein R^7 and R^8 , identical or different, each represent hydrogen, a linear or branched, optionally at least mono-substituted C_1 - C_4 alkyl radical,

preferably hydrogen or a C_1 - C_2 alkyl radical, with the proviso that R^7 and R^8 are not hydrogen at the same time.


13.- The compounds according to one or more of claims 10 to 12, characterized in that R^9 and R^{10} , identical or different, each represent hydrogen, a linear or branched, optionally at least mono-substituted C_1 - C_{10} alkyl radical, a linear or branched, optionally at least mono-substituted C_2 - C_{10} alkenyl radical, or a linear or branched, optionally at least mono-substituted C_2 - C_{10} alkynyl radical or

R^9 and R^{10} , together with the bridging nitrogen atom form a saturated or unsaturated, optionally at least mono-substituted, optionally at least one further heteroatom as a ring member containing 5- or 6-membered heterocyclic which may be condensed with a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom

as a ring member containing mono- or bicyclic cycloaliphatic ring system, whereby the rings of the ring system are 5- 6- or 7-membered.

- 14.- The compounds according to claim 13, characterized in that R^9 and R^{10} ,
 5 identical or different, each represent hydrogen or a linear or branched C_1 - C_{10} alkyl radical, or

R^9 and R^{10} , together with the bridging nitrogen atom form a radical chosen from a group consisting of



10

wherein R^{20} , if present, represents hydrogen, a linear or branched C_1 - C_6 alkyl radical or a benzyl radical, preferably hydrogen, or a C_1 - C_2 alkyl radical.

- 15.- The compounds according to one or more of claims 10 to 14,
 15 characterized in that A and B, together with the carbon atom to which they are bonded, form a saturated or unsaturated, but not aromatic, optionally at least mono-substituted cycloalkyl ring,


20 preferably a C_3 - C_8 cycloalkyl ring,

more preferably a cyclohexyl ring.

25


-60-

- 16.- A process for obtaining a sulfonamide derivative of general formula (Ia) and/or (Ib), according to one or more of claims 1 to 15, characterized in that at least one compound of general formula (II), or one of its suitably protected derivatives,



(II)

wherein A and B have the meaning according to one or more of claims 1 to 15 and X is an acceptable leaving group, preferably an halogen atom, more preferably chlorine, is reacted with at least one substituted indole of general formula (III)



(III)

wherein R^1 - R^6 and n have the meaning according to one or more of claims 1 to 15, or one of their suitable protected derivatives, and, if necessary, the protective groups are removed.

- 17.- A process for obtaining a sulfonamide derivative of general formula (Ia) and/or (Ib) according to one or more of claims 1-15, wherein one or more substituents R^2 , R^3 , R^4 , R^5 or R^6 represent a nitro group, characterized in that a sulfonamide derivative of corresponding general formula (Ia) and/or (Ib) is reduced to a sulfonamide derivative of corresponding

general formula (Ia) and/or (Ib), wherein one or more substituents R^2 , R^3 , R^4 , R^5 or R^6 represent an amino group.

- 18.- A process for preparing the salts, preferably the physiologically acceptable salts of the compounds of general formula (Ia) and/or (Ib), according to one or more of claims 1 to 15, consisting of reacting at least one compound of the general formula (Ia) and/or at least one compound of the general formula (Ib) with a mineral acid or organic acid in a suitable solvent.
- 19.- A medicament comprising at least one compound according to one or more of claims 1 to 9 and optionally one or more pharmacologically acceptable excipients.
- 20.- A medicament according to claim 19, for 5-HT₆ receptor regulation, for the prophylaxis and/or treatment of a disorder or disease related to food intake, preferably for the regulation of appetite, for the maintenance, increase or reduction of body weight, for the prophylaxis and/or treatment of obesity, bulimia, anorexia, cachexia or type II diabetes (non insulin dependent diabetes mellitus), preferably type II diabetes caused by obesity, for the prophylaxis and/or treatment of gastrointestinal tract disorders, preferably irritable bowel syndrome, for cognitive enhancement, for the prophylaxis and/or treatment of disorders of the central nervous system, anxiety, panic disorders, depression, preferably bipolar disorders, cognitive memory disorders, senile dementia processes, neurodegenerative disorders, preferably Alzheimer's disease, Parkinson's disease, Huntington's disease and/or multiple sclerosis, schizophrenia, psychosis or infantile hyperkinesia (ADHD, attention deficit / hyperactivity disorder),

preferably for 5-HT₆ receptor regulation, for the prophylaxis and/or treatment of a disorder or disease related to food intake, preferably for the regulation of appetite, for the maintenance, increase or reduction of body weight, for the prophylaxis and/or treatment of obesity, bulimia, anorexia, cachexia or type II diabetes (non insulin dependent diabetes mellitus), preferably type II diabetes caused by obesity, for the prophylaxis and/or treatment of gastrointestinal tract disorders, preferably irritable bowel syndrome.

- 10 21. - The use of at least one compound according to one or more of claims 1 to 9 for the manufacture of a medicament for 5-HT₆ receptor regulation.
- 22.- The use of at least one compound according to one or more of claims 1 to 9 for the manufacture of a medicament for the prophylaxis and/or treatment of a disorder or disease related to food intake.
- 15 23.- The use of at least one compound according to one or more of claims 1 to 9 for the manufacture of a medicament for the regulation of appetite.
- 20 24.- The use of at least one compound according to one or more of claims 1 to 9 for the manufacture of a medicament for the maintenance, increase or reduction of body weight.
- 25 25.- The use of at least one compound according to one or more of claims 1 to 9 for the manufacture of a medicament for the prophylaxis and/or treatment of obesity.
- 30 26.- The use of at least one compound according to one or more of claims 1 to 9 for the manufacture of a medicament for the prophylaxis and/or treatment of bulimia.

- 27.- The use of at least one compound according to one or more of claims 1 to 9 for the manufacture of a medicament the prophylaxis and/or treatment of anorexia.
- 5 28.- The use of at least one compound according to one or more of claims 1 to 9 for the manufacture of a medicament for the prophylaxis and/or treatment of cachexia.
- 10 29.- The use of at least one compound according to one or more of claims 1 to 9 for the manufacture of a medicament for the prophylaxis and/or treatment of type II diabetes (non insulin dependent diabetes mellitus), preferably type II diabetes caused by obesity.
- 15 30.- The use of at least one compound according to one or more of claims 1 to 9 for the manufacture of a medicament for the manufacture of a medicament for the prophylaxis and/or treatment of gastrointestinal tract disorders.
- 20 31.- The use of at least one compound according to one or more of claims 1 to 9 for the manufacture of a medicament for the prophylaxis and/or treatment of irritable bowel syndrome.
- 25 32.- The use of at least one compound according to one or more of claims 1 to 9 for the manufacture of a medicament for the prophylaxis and/or treatment of anxiety.
- 30 33.- The use of at least one compound according to one or more of claims 1 to 9 for the manufacture of a medicament for the prophylaxis and/or treatment of depression.

- 34.- The use of at least one compound according to one more of claims 1 to 9 for the manufacture of a medicament for the prophylaxis and/or treatment of bipolar disorders.
- 5 35. - The use of at least one compound according to one or more of claims 1 to 9 for the manufacture of a medicament for the prophylaxis and/or treatment of cognitive memory disorders.
- 10 36.- The use of at least one compound according to one or more of claims 1 to 9 for the manufacture of a medicament for the prophylaxis and/or treatment of senile dementia processes.
- 15 37.- The use of at least one compound according to one or more of claims 1 to 9 for the manufacture of a medicament for the prophylaxis and/or treatment of Alzheimer's Disease.
- 20 38.- The use of at least one compound according to one or more of claims 1 to 9 for the manufacture of a medicament for the prophylaxis and/or treatment of Parkinson's Disease.
- 25 39.- The use of at least one compound according to one or more of claims 1 to 9 for the manufacture of a medicament for the prophylaxis and/or treatment of Huntington's Disease.
- 30 40.- The use of at least one compound according to one or more of claims 1 to 9 for the manufacture of a medicament for the prophylaxis and/or treatment of Multiple Sclerosis.
- 41.- The use of at least one compound according to one or more of claims 1 to 9 for the manufacture of a medicament for the prophylaxis and/or treatment of dementias in which a cognitive deficit predominates.

- 42.- The use of at least one compound according to one or more of claims 1 to 9 for the manufacture of a medicament for the prophylaxis and/or treatment of psychosis.
- 5 43.- The use of at least one compound according to one or more of claims 1 to 9 for the manufacture of a medicament for the prophylaxis and/or treatment of infantile hyperkinesia (ADHD, attention deficit / hyperactivity disorder).
- 10 44.- The use of at least one compound according to one or more of claims 1 to 9 for the manufacture of a medicament for the prophylaxis and/or treatment of disorders of the central nervous system.
- 15 45.- The use of at least one compound according to one or more of claims 1 to 9 for the manufacture of a medicament for the prophylaxis and/or treatment of schizophrenia.
- 46.- The use of at least one compound according to one or more of claims 1 to 9 for the manufacture of a medicament for cognitive enhancement.
- 20 47. A medicament comprising at least one compound according to one or more of claims 9 to 15 and optionally at least one or more of pharmacologically acceptable excipients.
- 25 48.- A medicament according to claim 47 for 5-HT₆ receptor regulation, for the prophylaxis and/or treatment of a disorder or disease related to food intake, preferably for the regulation of appetite, for the maintenance, increase or reduction of body weight, for the prophylaxis and/or treatment of obesity, bulimia, anorexia, cachexia or type II diabetes (non insulin dependent diabetes mellitus), preferably type II diabetes caused by
- 30 obesity, for the prophylaxis and/or treatment of gastrointestinal tract disorders, preferably irritable bowel syndrome, for cognitive

enhancement, for the prophylaxis and/or treatment of disorders of the central nervous system, anxiety, panic disorders, depression, preferably bipolar disorders, cognitive memory disorders, senile dementia processes, neurodegenerative disorders, preferably Alzheimer's disease, Parkinson's disease, Huntington's disease and/or multiple sclerosis, schizophrenia, psychosis or infantile hyperkinesia (ADHD, attention deficit / hyperactivity disorder),

preferably for cognitive enhancement, for the prophylaxis and/or treatment of disorders of the central nervous system, anxiety, panic disorders, depression, preferably bipolar disorders, cognitive memory disorders, senile dementia processes, neurodegenerative disorders, preferably Alzheimer's disease, Parkinson's disease, Huntington's disease and multiple sclerosis, schizophrenia, psychosis or infantile hyperkinesia (ADHD, attention deficit / hyperactivity disorder).

49.- The use of at least one compound according to one or more of claims 10 to 15 for the manufacture of a medicament for 5-HT₆ receptor regulation.

50.- The use of at least one compound according to one or more of claims 9 to 15 for the manufacture of a medicament for the prophylaxis and/or treatment of a disorder or disease related to food intake.

51.- The use of at least one compound according to one or more of claims 10 to 15 for the manufacture of a medicament for the regulation of appetite.

52.- The use of at least one compound according to one or more of claims 10 to 15 for the manufacture of a medicament for the maintenance, increase or reduction of body weight.

- 53.- The use of at least one compound according to one or more of claims 10 to 15 for the manufacture of a medicament for the prophylaxis and/or treatment of obesity.
- 5 54.- The use of at least one compound according to one or more of claims 10 to 15 for the manufacture of a medicament for the prophylaxis and/or treatment of bulimia.
- 10 55.- The use of at least one compound according to one or more of claims 10 to 15 for the manufacture of a medicament for the prophylaxis and/or treatment of anorexia.
- 15 56.- The use of at least one compound according to one or more of claims 10 to 15 for the manufacture of a medicament for the prophylaxis and/or treatment of cachexia.
- 20 57.- The use of at least one compound according to one or more of claims 10 to 15 for the manufacture of a medicament for the prophylaxis and/or treatment of type II diabetes (non-insulin-dependent diabetes mellitus), preferably type II diabetes caused by obesity.
- 25 58.- The use of at least one compound according to one or more of claims 10 to 15 for the manufacture of a medicament for the prophylaxis and/or treatment of gastrointestinal tract disorders.
- 59.- The use of at least one compound according to one or more of claims 10 to 15 for the manufacture of a medicament for the prophylaxis and/or treatment of irritable bowel syndrome.
- 30 60.- The use of at least one compound according to one or more of claims 10 to 15 for the manufacture of a medicament for the prophylaxis and/or treatment of anxiety.

- 61.- The use of at least one compound according to one or more of claims 10 to 15 for the manufacture of a medicament for the prophylaxis and/or treatment of depression.
- 5 62.- The use of at least one compound according to one or more of claims 10 to 15 for the manufacture of a medicament for the prophylaxis and/or treatment of bipolar disorders.
- 10 63.- The use of at least one compound according to one or more of claims 10 to 15 for the manufacture of a medicament for the prophylaxis and/or treatment of cognitive memory disorders.
- 15 64.- The use of at least one compound according to one or more of claims 10 to 15 for the manufacture of a medicament for the prophylaxis and/or treatment of senile dementia processes.
- 20 65.- The use of at least one compound according to one or more of claims 10 to 15 for the manufacture of a medicament for the prophylaxis and/or treatment of Alzheimer's Disease.
- 25 66.- The use of at least one compound according to one or more of claims 10 to 15 for the manufacture of a medicament for the prophylaxis and/or treatment of Parkinson's Disease.
- 67.- The use of at least one compound according to one or more of claims 10 to 15 for the manufacture of a medicament for the prophylaxis and/or treatment of Huntington's Disease.
- 30 68.- The use of at least one compound according to one or more of claims 10 to 15 for the manufacture of a medicament for the prophylaxis and/or treatment of Multiple Sclerosis.

- 69.- The use of at least one compound according to one or more of claims 10 to 15 for the manufacture of a medicament for the prophylaxis and/or treatment of dementias in which a cognitive deficit predominates.
- 5 70.- The use of at least one compound according to one or more of claims 10 to 15 for the manufacture of a medicament for the prophylaxis and/or treatment of psychosis.
- 10 71.- The use of at least one compound according to one or more of claims 10 to 15 for the manufacture of a medicament for the prophylaxis and/or treatment of infantile hyperkinesia (ADHD, attention deficit / hyperactivity disorder).
- 15 72.- The use of at least one compound according to one or more of claims 10 to 15 for the manufacture of a medicament for the prophylaxis and/or treatment of disorders of the central nervous system.
- 20 73.- The use of at least one compound according to one or more of claims 10 to 15 for the manufacture of a medicament for the prophylaxis and/or treatment of schizophrenia.
74. - The use of at least one compound according to one or more of claims 10 to 15 for the manufacture of a medicament for cognitive enhancement.